Bimagrumab
An investigational anti-activin type II receptor monoclonal antibody given by infusion that adds skeletal muscle while reducing fat mass. It is being studied alongside GLP-1 therapies and is not approved.
- Half-life
- 10.0 d
- Out of system
- ~7 weeks
- Route
- Intravenous
- Level
- Advanced
Long-acting — weekly dosing keeps levels steady. After the last dose, roughly 97% has cleared in ~7 weeks (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What Bimagrumab is used for
- Increases skeletal muscle mass by blocking activin type II receptor signaling
- Reduces fat mass while adding muscle, a distinct body-composition profile
- Studied in combination with GLP-1 therapy to protect lean mass
How it's typically used
Trial range: administered as periodic intravenous infusions per study protocol, as reported in the literature.
What to watch for
- Can cause muscle cramps, diarrhea and mild acne-like effects in trials
- Given by intravenous infusion, requiring a clinical setting
- Investigational; not approved for any use
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Full guide
Bimagrumab: A Tracking Guide for an Activin Receptor Antibody
A harm-reduction look at bimagrumab, an investigational antibody that lowers fat while preserving or adding muscle, studied with semaglutide.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.